Acinic cell carcinoma classification: Difference between revisions

	Acinic cell carcinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Acinic cell carcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Surgery
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case studies
Case #1
Acinic cell carcinoma classification On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Acinic cell carcinoma classification All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Acinic cell carcinoma classification
CDC on Acinic cell carcinoma classification
Acinic cell carcinoma classification in the news
Blogs on Acinic cell carcinoma classification
Directions to Hospitals Treating Acinic cell carcinoma
Risk calculators and risk factors for Acinic cell carcinoma classification

← Older edit Newer edit →

VisualWikitext

Revision as of 14:52, 4 September 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD [2]

Overview

There is no established system for the classification of [disease name].

OR

[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].

OR

[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].

OR

Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

OR

If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

OR

The staging of [malignancy name] is based on the [staging system].

OR

There is no established system for the staging of [malignancy name].

Classification

According to the8th eddition of American Joint Committee on Cancer(AJCC) and Union for International Cancer Control (UICC)the staging of salivary gland neoplasms are staged by TNM system.^[1] This means acinic cell carcinoma is staged based on tumor, node, and metastasissimilar to squamous cell carcinoma.

T category	N category	M category
TX: Primary tumor cannot be assessed	NX: Regional lymph nodes cannot be assessed	M0: No distant metastasis
T0: No evidence of primary tumor	N0: No regional lymph node metastasis	M1: Distant metastasis
Tis: Carcinoma in situ	N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(–)
T1: Tumor 2 cm or smaller in greatest dimension without extraparenchymal extension	N2:Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or Larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(–); or Metastases in multiple ipsilateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(–); or In bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(–)
T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension without extraparenchymal extension	N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+); or A single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(–)
T3: Tumor larger than 4 cm and/or tumor having extraparenchymal extension	N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(–)
T4a: Moderately advanced disease. Tumor invades skin, mandible, ear canal, and/or facial nerve.	N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(–)
T4b:Very advanced disease. Tumor invades skull base and/or pterygoid plates and/or encases carotid artery.	N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(–); or In a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or Multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); or A single contralateral node of any size and ENE(+)
	N3a: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(–)
	N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or Multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); or A single contralateral node of any size and ENE(+)

References

↑ Son, Eugene; Panwar, Aru; Mosher, Charles H.; Lydiatt, Daniel (2018). "Cancers of the Major Salivary Gland". Journal of Oncology Practice. 14 (2): 99–108. doi:10.1200/JOP.2017.026856. ISSN 1554-7477.

Template:WH Template:WS

[SonPanwar2018-1] Son, Eugene; Panwar, Aru; Mosher, Charles H.; Lydiatt, Daniel (2018). "Cancers of the Major Salivary Gland". Journal of Oncology Practice. 14 (2): 99–108. doi:10.1200/JOP.2017.026856. ISSN 1554-7477.

[1]

@@ Line 33: / Line 33: @@
 ==Classification==
-There is no established system for the classification of [disease name].
+According to the8th eddition of American Joint Committee on Cancer(AJCC) and Union for International Cancer Control (UICC)the staging of salivary gland neoplasms are staged by [[TNM system]].<ref name="SonPanwar2018">{{cite journal|last1=Son|first1=Eugene|last2=Panwar|first2=Aru|last3=Mosher|first3=Charles H.|last4=Lydiatt|first4=Daniel|title=Cancers of the Major Salivary Gland|journal=Journal of Oncology Practice|volume=14|issue=2|year=2018|pages=99–108|issn=1554-7477|doi=10.1200/JOP.2017.026856}}</ref> This means acinic cell carcinoma is staged based on tumor, node, and metastasissimilar to squamous cell carcinoma.
-OR
+<br />
+{| class="wikitable"
-[Disease name] may be classified according to [classification method] into [number] subtypes/groups:
+!T category
-*[Group1]
+!N category
-*[Group2]
+!M category
-*[Group3]
+|-
-*[Group4]
+|TX: Primary tumor cannot be assessed
+|NX: Regional lymph nodes cannot be assessed
-OR
+|M0: No distant metastasis
+|-
-[Disease name] may be classified into [large number > 6] subtypes based on:
+|T0: No evidence of primary tumor
-*[Classification method 1]
+|N0: No regional lymph node metastasis
-*[Classification method 2]
+|M1: Distant metastasis
-*[Classification method 3]
+|-
+|Tis: Carcinoma ''in situ''
-[Disease name] may be classified into several subtypes based on:
+|N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(–)
-*[Classification method 1]
+|
-*[Classification method 2]
+|-
-*[Classification method 3]
+|T1: Tumor 2 cm or smaller in greatest dimension without extraparenchymal extension
+|N2:Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); '''or'''
-OR
+Larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(–); '''or'''
+Metastases in multiple ipsilateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(–); '''or'''
-Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
+In bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(–)
+|
-OR
+|-
+|T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension without extraparenchymal extension
-'''If the staging system involves specific and characteristic findings and features:'''
+|N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+); '''or'''
+A single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(–)
-According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
+|
+|-
-OR
+|T3: Tumor larger than 4 cm and/or tumor having extraparenchymal extension
+|N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(–)
-The staging of [malignancy name] is based on the [staging system].
+|
+|-
-OR
+|T4a: Moderately advanced disease.
+Tumor invades skin, mandible, ear canal, and/or facial nerve.
-There is no established system for the staging of [malignancy name].
+|N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(–)
+|
+|-
+|T4b:Very advanced disease.
+Tumor invades skull base and/or pterygoid plates and/or encases carotid artery.
+|N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(–); '''or'''
+In a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); '''or'''
+Multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); '''or'''
+A single contralateral node of any size and ENE(+)
+|
+|-
+|
+|N3a: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(–)
+|
+|-
+|
+|N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); '''or'''
+Multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); '''or'''
+A single contralateral node of any size and ENE(+)
+|
+|}
 ==References==

Acinic cell carcinoma classification: Difference between revisions

Revision as of 14:52, 4 September 2019

Overview

Classification

References

Navigation menu

Search